Search

Your search keyword '"Ghielmini, Michele"' showing total 384 results
Start Over Author "Ghielmini, Michele"
384 results on '"Ghielmini, Michele"'

2. Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials

Author

Dixon, Jesse G., Çağlayan, Çağlar, Chihara, Dai, Nielsen, Tina, Dimier, Natalie, Zheng, Jamie, Wall, Anna K., Salles, Gilles, Morschhauser, Franck, Marcus, Robert, Herold, Michael, Kimby, Eva, Blum, Kristie A., Ghielmini, Michele, Shi, Qian, and Flowers, Christopher R.

Published
2022
Full Text
View/download PDF

3. Follicular Lymphoma

Author

Moccia, Alden A., Dreyling, Martin, Ghielmini, Michele, Dreyling, Martin, Series Editor, and Ladetto, Marco, editor

Published
2021
Full Text
View/download PDF

4. Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial

Author

Moccia, Alden A., Taverna, Christian, Schär, Sämi, Vanazzi, Anna, Rondeau, Stéphanie, Hitz, Felicitas, Mingrone, Walter, Pabst, Thomas, Cevreska, Lidija, del Giglio, Auro, Raats, Johann, Rauch, Daniel, Vorobiof, Daniel A., Lohri, Andreas, Ruegsegger, Céline, Biaggi Rudolf, Christine, Rusterholz, Corinne, Hayoz, Stefanie, Ghielmini, Michele, and Zucca, Emanuele

Published
2020
Full Text
View/download PDF

5. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Author

Zucca, Emanuele, Rondeau, Stephanie, Vanazzi, Anna, Østenstad, Bjørn, Mey, Ulrich J.M., Rauch, Daniel, Wahlin, Björn E., Hitz, Felicitas, Hernberg, Micaela, Johansson, Ann-Sofie, de Nully Brown, Peter, Hagberg, Hans, Ferreri, Andrés J.M., Lohri, Andreas, Novak, Urban, Zander, Thilo, Bersvendsen, Hanne, Bargetzi, Mario, Mingrone, Walter, Krasniqi, Fatime, Dirnhofer, Stefan, Hayoz, Stefanie, Hawle, Hanne, Vilei, Simona Berardi, Ghielmini, Michele, and Kimby, Eva

Published
2019
Full Text
View/download PDF

7. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma

Author

Spina, Valeria, Bruscaggin, Alessio, Cuccaro, Annarosa, Martini, Maurizio, Di Trani, Martina, Forestieri, Gabriela, Manzoni, Martina, Condoluci, Adalgisa, Arribas, Alberto, Terzi-Di-Bergamo, Lodovico, Locatelli, Silvia Laura, Cupelli, Elisa, Ceriani, Luca, Moccia, Alden A., Stathis, Anastasios, Nassi, Luca, Deambrogi, Clara, Diop, Fary, Guidetti, Francesca, Cocomazzi, Alessandra, Annunziata, Salvatore, Rufini, Vittoria, Giordano, Alessandro, Neri, Antonino, Boldorini, Renzo, Gerber, Bernhard, Bertoni, Francesco, Ghielmini, Michele, Stüssi, Georg, Santoro, Armando, Cavalli, Franco, Zucca, Emanuele, Larocca, Luigi Maria, Gaidano, Gianluca, Hohaus, Stefan, Carlo-Stella, Carmelo, and Rossi, Davide

Published
2018
Full Text
View/download PDF

9. Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study

Author

Ghilardi, Guido, Pabst, Thomas, Jeker, Barbara, Müller, Rouven, Cairoli, Anne, Müller, Antonia M. S., Bargetzi, Mario, Hitz, Felicitas, Baldomero, Helen, Heim, Dominik, Schmidt, Adrian, Rossi, Davide, Ghielmini, Michele, Wannesson, Luciano, Lerch, Erika, Samaras, Panagiotis, Schanz, Urs, Passweg, Jakob R., Stussi, Georg, Kleber, Martina, Gerber, Bernhard, and On behalf of the Swiss Blood Stem Cell Transplantation Registry

Published
2019
Full Text
View/download PDF

10. Rituximab maintenance improves overall survival of patients with follicular lymphoma—Individual patient data meta-analysis

Author

Vidal, Liat, Gafter-Gvili, Anat, Salles, Gilles, Bousseta, Sami, Oberman, Bernice, Rubin, Carmit, van Oers, Marinus H.J., Fortpied, Catherine, Ghielmini, Michele, Pettengell, Ruth, Witzens-Harig, Mathias, Dreger, Peter, Vitolo, Umberto, Gomes da Silva, Maria, Evangelista, Andrea, Li, Hailun, Freedman, Laurence, Habermann, Thomas M., and Shpilberg, Ofer

Published
2017
Full Text
View/download PDF

16. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)

Author

Moccia, Alden Alberto, Schär, Sämi, Hayoz, Stefanie, Pirosa, Maria Cristina, Taverna, Christian, Novak, Urban, Kimby, Eva, Ghielmini, Michele, and Zucca, Emanuele

Subjects
610 Medicine & health
Abstract

The relapse of follicular lymphoma (FL) within 24 months (POD24) of chemoimmunotherapy has been associated with poor survival. We analyzed a pooled dataset of three randomized trials including FL patients with advanced disease, conducted by the Swiss Group for Clinical Cancer Research (SAKK). Overall, POD24 was observed in 27% of 318 patients, but rate variance among studies suggested that the rituximab schedule might affect POD24 rate. POD24 was associated with lower 10-year overall survival rates than in the reference group (69% vs. 77%; hazard ratio, 3·12; 95% confidence interval, 1·73-5·65). POD24 retains its prognostic validity in patients treated without chemotherapy and may represent a useful end-point for future studies.

Published
2020
Full Text
View/download PDF

17. Evaluation of the Different Stratification Models for POD24 Prediction in Patients with Follicular Lymphoma

Author

Wu, Wei, primary, Bruscaggin, Alessio, additional, Valera, Alexandra, additional, Flospergher, Elena, additional, Bonfiglio, Ferdinando, additional, Spina, Valeria, additional, Terzi-di-Bergamo, Lodovico, additional, Moccia, Alden, additional, Moia, Riccardo, additional, Ruffini, Alessia, additional, Stathis, Anastasios, additional, Faderl, Martin, additional, Koch, Ricardo, additional, Forestieri, Gabriela, additional, Pini, Katia, additional, Condoluci, Adalgisa, additional, Pirosa, Maria Cristina, additional, Gerber, Bernhard, additional, Gillessen, Silke, additional, Stüssi, Georg, additional, Ghielmini, Michele, additional, Cavalli, Franco, additional, Luminari, Stefano, additional, Boldorini, Renzo, additional, Mazzucchelli, Luca, additional, Gaidano, Gianluca, additional, Rossi, Davide, additional, and Zucca, Emanuele, additional

Published
2020
Full Text
View/download PDF

20. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)

Author

Ghielmini, M., Vitolo, U., Kimby, E., Montoto, S., Walewski, J., Pfreundschuh, M., Federico, M., Hoskin, P., McNamara, C., Caligaris-Cappio, F., Stilgenbauer, S., Marcus, R., Trneny, M., Dreger, P., Montserrat, E., Dreyling, M., Agostinelli, Claudio, Arcaini, Luca, Caligaris-Cappio, Federico, Campo, Elias, Coiffier, Bertrand, Corradini, Paolo, DʼAmore, Francesco, Dreger, Peter, Dreyling, Martin, Federico, Massimo, Gallamini, Andrea, Gaulard, Philippe, Geisler, Christian H., Ghielmini, Michele, Gisselbrecht, Christian, da Silva, Maria Gomes, Gribben, John, Hermine, Olivier, Hoskin, Peter, Iannitto, Emilio, Kim, Won Seog, Kimby, Eva, Kluin-Nelemans, Hanneke C., Koch, Peter, Ladetto, Marco, Le Gouill, Steven, Lopez-Guillermo, Armando, Marcus, Robert, McNamara, Christopher, Montalban, Carlos, Montoto, Silvia, Montserrat, Emili, Pfreundschuh, Michael, Raderer, Markus, Rodriguez, José, Salles, Gilles, Bernard, Claude, Schmitz, Norbert, Shpilberg, Ofer, Stilgenbauer, Stephan, Thieblemont, Catherine, Tilly, Hervé, Tournilhac, Olivier, Trümper, Lorenz, Vitolo, Umberto, Walewski, Jan, Wotherspoon, Andrew, and Zucca, Emanuele

Published
2013
Full Text
View/download PDF

26. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy‐free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)

Author

Moccia, Alden Alberto, primary, Schär, Sämi, additional, Hayoz, Stefanie, additional, Pirosa, Maria Cristina, additional, Taverna, Christian, additional, Novak, Urban, additional, Kimby, Eva, additional, Ghielmini, Michele, additional, and Zucca, Emanuele, additional

Published
2020
Full Text
View/download PDF

27. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia

Author

Condoluci, Adalgisa, primary, Terzi di Bergamo, Lodovico, primary, Langerbeins, Petra, primary, Hoechstetter, Manuela A., primary, Herling, Carmen D., primary, De Paoli, Lorenzo, primary, Delgado, Julio, primary, Rabe, Kari G., primary, Gentile, Massimo, primary, Doubek, Michael, primary, Mauro, Francesca R., primary, Chiodin, Giorgia, primary, Mattsson, Mattias, primary, Bahlo, Jasmin, primary, Cutrona, Giovanna, primary, Kotaskova, Jana, primary, Deambrogi, Clara, primary, Smedby, Karin E., primary, Spina, Valeria, primary, Bruscaggin, Alessio, primary, Wu, Wei, primary, Moia, Riccardo, primary, Bianchi, Elena, primary, Gerber, Bernhard, primary, Zucca, Emanuele, primary, Gillessen, Silke, primary, Ghielmini, Michele, primary, Cavalli, Franco, primary, Stussi, Georg, primary, Hess, Mark A., primary, Baumann, Tycho S., primary, Neri, Antonino, primary, Ferrarini, Manlio, primary, Rosenquist, Richard, primary, Forconi, Francesco, primary, Foà, Robin, primary, Pospisilova, Sarka, primary, Morabito, Fortunato, primary, Stilgenbauer, Stephan, primary, Döhner, Hartmut, primary, Parikh, Sameer A., primary, Wierda, William G., primary, Montserrat, Emili, primary, Gaidano, Gianluca, primary, Hallek, Michael, primary, and Rossi, Davide, primary

Published
2020
Full Text
View/download PDF

30. A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group

Author

Caglayan, Caglar, primary, Dixon, Jesse, additional, Wall, Anna, additional, Salles, Gilles A., additional, Hoster, Eva, additional, Hiddemann, Wolfgang, additional, Herold, Michael, additional, Morschhauser, Franck, additional, Sebban, Catherine, additional, Hagenbeek, Anton, additional, Marcus, Robert, additional, Hochster, Howard, additional, Rummel, Mathias J, additional, Kimby, Eva, additional, Vitolo, Umberto, additional, Peterson, Bruce A., additional, Gyan, Emmanuel, additional, Ladetto, Marco, additional, Foussard, Charles Yves, additional, Ghielmini, Michele, additional, Nielsen, Tina G, additional, Foon, Kenneth, additional, Shi, Qian, additional, and Flowers, Christopher R., additional

Published
2019
Full Text
View/download PDF

41. European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma

Author

Foran, James M., Rohatiner, Ama Z. S., Cunningham, David, Popescu, Razvan A., Solal-Celigny, Philippe, Ghielmini, Michele, Coiffier, Bertrand, Johnson, Peter W. M., Gisselbrecht, Christian, Reyes, Felix, Radford, John A., Bessell, Eric M., Souleau, Bertrand, Benzohra, Aziz, and Lister, T. Andrew

Published
2000

43. International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia

Author

Condoluci, Adalgisa, primary, di Bergamo, Lodovico Terzi, additional, Langerbeins, Petra, additional, Hoechstetter, Manuela, additional, Herling, Carmen, additional, De Paoli, Lorenzo, additional, Delgado, Julio, additional, Rabe, Kari G., additional, Gentile, Massimo, additional, Doubek, Michael, additional, Mauro, Francesca Romana, additional, Chiodin, Giorgia, additional, Mattsson, Mattias, additional, Bahlo, Jasmin, additional, Cutrona, Giovanna, additional, Kotaskova, Jana, additional, Deambrogi, Clara, additional, Spina, Valeria, additional, Bruscaggin, Alessio, additional, Moia, Riccardo, additional, Bianchi, Elena, additional, Gerber, Bernhard, additional, Zucca, Emanuele, additional, Ghielmini, Michele, additional, Cavalli, Franco, additional, Stüssi, Georg, additional, Neri, Antonino, additional, Ferrarini, Manlio, additional, Rosenquist, Richard, additional, Forconi, Francesco, additional, Foà, Robin, additional, Pospisilova, Sarka, additional, Morabito, Fortunato, additional, Parikh, Sameer A., additional, Wierda, William G., additional, Montserrat, Emili, additional, Gaidano, Gianluca, additional, Hallek, Michael, additional, and Rossi, Davide, additional

Published
2019
Full Text
View/download PDF

44. Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03

Author

Taverna, Christian, primary, Martinelli, Giovanni, additional, Hitz, Felicitas, additional, Mingrone, Walter, additional, Pabst, Thomas, additional, Cevreska, Lidija, additional, del Giglio, Auro, additional, Vanazzi, Anna, additional, Laszlo, Daniele, additional, Raats, Johann, additional, Rauch, Daniel, additional, Vorobiof, Daniel, additional, Lohri, Andreas, additional, Zucca, Emanuele, additional, Rueegsegger, Celine, additional, Rondeau, Stephanie -, additional, Rusterholz, Corinne, additional, and Ghielmini, Michele, additional

Published
2018
Full Text
View/download PDF

45. External Validation and Revision of Thrombosis Lymphoma /Throly/ Score

Author

Antic, Darko, primary, Milic, Natasa, additional, Mihaljevic, Biljana, additional, Cheson, Bruce, additional, Narkhede, Mayur, additional, Abdel-Razeq, Hikmat, additional, Panovska, Irina, additional, Trajkova, Sanja, additional, Popova, Marija, additional, Aurer, Igor, additional, Boban, Ana, additional, Ghielmini, Michele, additional, Moccia, Alden, additional, Delluc, Aurelien, additional, Ianotto, Jean-Christophe, additional, Jaeger, Ulrich, additional, Skrabs, Cathrin, additional, Gerotziafas, Grigorios T., additional, and Fareed, Jawed, additional

Published
2018
Full Text
View/download PDF

46. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

Author

Galimberti, Viviana, primary, Cole, Bernard F, additional, Viale, Giuseppe, additional, Veronesi, Paolo, additional, Vicini, Elisa, additional, Intra, Mattia, additional, Mazzarol, Giovanni, additional, Massarut, Samuele, additional, Zgajnar, Janez, additional, Taffurelli, Mario, additional, Littlejohn, David, additional, Knauer, Michael, additional, Tondini, Carlo, additional, Di Leo, Angelo, additional, Colleoni, Marco, additional, Regan, Meredith M, additional, Coates, Alan S, additional, Gelber, Richard D, additional, Goldhirsch, Aron, additional, Boyle, Fran, additional, Jerusalem, Guy, additional, Stahel, Rolf, additional, Aebi, Stefan, additional, Green, Michael, additional, Karlsson, Per, additional, Kössler, Ingrid, additional, Láng, Istvan, additional, Hiltbrunner, Anita, additional, Bernhard, Jürg, additional, Fournarakou, Stamatina, additional, Kammler, Roswitha, additional, Maibach, Rudolf, additional, Rabaglio, Manuela, additional, Ribi, Karin, additional, Roschitzki, Heidi, additional, Roux, Susanne, additional, Ruepp, Barbara, additional, Mahoney, Caitlin, additional, Price, Karen, additional, Blacher, Lynette, additional, Scolese, Tara, additional, Scott, Karolyn, additional, Lippert, Sandra, additional, Zielinski, Theresa, additional, Mastropasqua, Mauro, additional, Andrighetto, Stefania, additional, Dell'Orto, Patrizia, additional, Renne, Giuseppe, additional, Pruneri, Giancarlo, additional, Dellapasqua, Silvia, additional, Iorfida, Monica, additional, Cancello, Giuseppe, additional, Montagna, Emilia, additional, Cardillo, Anna, additional, Peruzzotti, Giulia, additional, Ghisini, Raffaella, additional, Luini, Alberto, additional, Veronesi, Umberto, additional, Gentilini, Oreste, additional, Zurrida, Stefano, additional, Curigliano, Giuseppe, additional, Nole, Franco, additional, Orecchia, Roberto, additional, Leonardi, Marisa Cristina, additional, Baratella, Paola, additional, Chifu, Camelia, additional, Sargenti, Manuela, additional, Crivellari, Diana, additional, Morassut, Sandro, additional, Mileto, Mario, additional, Piccoli, Erica, additional, Veronesi, Andreas, additional, Magri, Marisa Donatella, additional, Buonadonna, Angelo, additional, Candiani, Ezio, additional, Carbone, Antonino, additional, Perin, Tiziana, additional, Volpe, Rachele, additional, Roncadin, Mario, additional, Arcicasa, Mauro, additional, Coran, Francesco, additional, Lagrassa, Manuela, additional, Recalcati, Angelo, additional, Limonta, Maria Emanuela, additional, Tricomi, Paolo, additional, Fenaroli, Privato, additional, Candiago, Elisabetta, additional, Cattaneo, Laura, additional, Gianatti, Alberto, additional, Santini, Donatella, additional, Maweja, Sylvie, additional, Delvenne, Philippe, additional, Rorive, Andrée, additional, Collignon, Joëlle, additional, Garbay, Jean-Remi, additional, Mathieu, Marie-Christine, additional, Galatius, Hanne, additional, Hoffmann, Jack, additional, Schousen, Peer, additional, Lanng, Charlotte, additional, Hoerby, John, additional, Bruun Rasmussen, Birgitte, additional, Holtveg, Helle, additional, Moeller Talman, Maj-Lis, additional, Abugattas, Julio Elías, additional, Cotrina, Jose Manuel, additional, Dyer, Richard, additional, Lindtner, Jurij, additional, Majdic, Elga, additional, Frkovic-Grazio, Snjezana, additional, Oehlschlegel, Christian, additional, Ries, Gerhard, additional, Töpfer, Michael, additional, Lorenz, Ute, additional, Schiltknecht, Otto, additional, Späti, Bruno, additional, Ehrsam, Andreas, additional, Bamert, Monika, additional, Egli-Tupaj, Martina, additional, Rageth, Christoph, additional, Saurenmann, Elisabeth, additional, Tausch, Christoph, additional, Caduff, Rosmarie, additional, Moch, Holger, additional, Varga, Zsuzsanna, additional, Sarlos, Dimitri, additional, Kralidis, Elena, additional, Grobholz, Rainer, additional, Pagani, Olivia, additional, Bronz, Lucia, additional, Ghielmini, Michele, additional, Mazzucchelli, Luca, additional, Rusca, Tiziana, additional, Gyr, Thomas, additional, Leidi, Linda, additional, Caccia, Giorgio, additional, Wyss, Daniel, additional, Fey, Martin F., additional, Müller, Michael, additional, Günthert, Andreas, additional, Berclaz, Gilles, additional, Fleischmann, Achim, additional, Delaloye, Jean Francois, additional, Treboux, Assia, additional, Lehr, Hans-Anton, additional, Fiche, Maryse, additional, Perey, Lucien, additional, Zaman, Lucien, additional, Jeanneret Sozzi, Wendy, additional, Forbes, John, additional, Lindsay, D.F., additional, Preece, D.F., additional, Hill, Jane, additional, Jeal, P., additional, Smart, P., additional, Collins, John, additional, Mann, Gregory Bruce, additional, Millar, Robert, additional, Murphy, Craig, additional, Buchanan, Malcolm, additional, Murugasu, Anand, additional, French, James, additional, Elder, Elisabeth, additional, Mann, Lynette, additional, Moon, David, additional, Bilous, A. Michael, additional, Pathmanathan, Nirmala, additional, Howard, Virginia, additional, Gill, Petere G., additional, Kollias, James, additional, Bochner, Melissa, additional, Madigan, Linda, additional, Rippy, Elisabeth, additional, Whitfield, Robert, additional, Farshidi, Fereshte, additional, Moore, Katrina, additional, Sywak, Mark, additional, Tan, L., additional, Ross, William, additional, Briscoe, Karen, additional, Jones, Allison, additional, Shah, Aashit, additional, Lim, Elgene, additional, Macindoe, Robert, additional, Spillane, Andrew, additional, Bonar, S. Fiona, additional, Carmalt, Hugh, additional, West, Richard, additional, Mak, Cindy, additional, McKenzie, Paul, additional, Harman, Richard, additional, Gerred, Susanne, additional, Juhasz, Eva, additional, Allpress, Stephen, additional, Craik, Julie, additional, Campbell, Ian, additional, Chin, Paul, additional, Hayes, Lori, additional, Mayall, Frederick, additional, and Thorburn, M., additional

Published
2018
Full Text
View/download PDF

47. Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy‐free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK).

Author

Moccia, Alden Alberto, Schär, Sämi, Hayoz, Stefanie, Pirosa, Maria Cristina, Taverna, Christian, Novak, Urban, Kimby, Eva, Ghielmini, Michele, and Zucca, Emanuele

Subjects
PROGNOSIS, CANCER research, LYMPHOMAS, RITUXIMAB
Abstract

Summary: The relapse of follicular lymphoma (FL) within 24 months (POD24) of chemoimmunotherapy has been associated with poor survival. We analyzed a pooled dataset of three randomized trials including FL patients with advanced disease, conducted by the Swiss Group for Clinical Cancer Research (SAKK). Overall, POD24 was observed in 27% of 318 patients, but rate variance among studies suggested that the rituximab schedule might affect POD24 rate. POD24 was associated with lower 10‐year overall survival rates than in the reference group (69% vs. 77%; hazard ratio, 3·12; 95% confidence interval, 1·73–5·65). POD24 retains its prognostic validity in patients treated without chemotherapy and may represent a useful end‐point for future studies. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

49. Y(90) -Ibritumomab tiuxetan (Y(90) -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05)

Author

Ketterer, Nicolas, Bischof Delaloye, Angelika, Berardi Vilei, Simona, Wannesson, Luciano, Rentschler, Jochen, Jost, Lorenz, Pabst, Thomas, Voegeli, Michèle, Lerch, Erika, Rondeau, Stephanie, Ghielmini, Michele, and Bargetzi, Mario

Subjects
610 Medicine & health
Abstract

Standard conditioning regimens for autologous stem cell transplantation (ASCT) are often not tolerated by elderly patients, on one hand. Single high-dose melphalan, on the other hand, has been shown to be safe and active as a pretransplant preparative regimen in elderly patients. Y(90) -Ibritumomab tiuxetan (Y(90) -IT) is well tolerated and feasible in the transplantation setting. We therefore investigated the combination of high-dose melphalan and Y(90) -IT as a conditioning regimen for patients ≥65 years of age. Patients with relapsed or resistant CD20-positive lymphoma in remission after salvage chemotherapy could be enrolled. High-dose therapy consisted of standard dose Y(90) -IT (0.4-mCi/kg body weight) followed by melphalan at escalating doses (100, 140, 170 and 200 mg/m(2) ) and ASCT. The primary objective was to identify the maximum tolerated dose; secondary end points were complete response (CR) rate 100 days after transplantation and toxicity. Twenty patients (median age 72 years) were included. No DLT occurred at any dose level. Thirteen patients completed the treatment, 11 were evaluable for response. Seven patients did not complete treatment because of mobilization failure (n = 3), progressive disease (n = 2), worsening of cardiac function (n = 1), and grade 3 dyspnea (n = 1). Seven patients achieved a CR/complete remission/unconfirmed (CRu) and 2 had stable disease. Five out of 7 responding patients were still alive more than 3 years after transplantation. The 2 patients with SD had a long-term survival of 3 and 5 years, respectively. Nonhematological grade 3 or higher treatment related adverse events (AEs) were infection (n = 6), including 2 cases of febrile neutropenia, diarrhea (n = 3), mucositis, anorexia, viral hepatitis, hypokalemia, dehydration, and multiorgan failure (n = 1 for each). The combination of Y(90) -IT and high-dose melphalan is feasible before ASCT for elderly patients, with promising activity and manageable toxicity.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results